References
Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016;3:e340–51. https://doi.org/10.1016/S2352-3026(16)30049-7.
Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:874–85. https://doi.org/10.1016/S1470-2045(14)70245-1.
Atanackovic D, Schilling G. Second autologous transplant as salvage therapy in multiple myeloma. Br J Haematol. 2013;163:565–72. https://doi.org/10.1111/bjh.12579.
Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20. https://doi.org/10.1200/JCO.2005.04.242.
Vincent Rajkumar S. Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89:999–1009. https://doi.org/10.1002/ajh.23810.
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73. https://doi.org/10.1038/sj.leu.2404284.
Singh Abbi KK, Zheng J, Devlin SM, Giralt S, Landau H. Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma. Biol Blood Marrow Transplant. 2015;21:468–72. https://doi.org/10.1016/j.bbmt.2014.11.677.
Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G, et al. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer. 2012;118:3549–55. https://doi.org/10.1002/cncr.26662.
Grovdal M, Nahi H, Gahrton G, Liwing J, Waage A, Abildgaard N, et al. Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. Bone Marrow Transplant. 2015;50:808–12. https://doi.org/10.1038/bmt.2015.39.
Jimenez-Zepeda VH, Mikhael J, Winter A, Franke N, Masih-Khan E, Trudel S, et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant. 2012;18:773–9. https://doi.org/10.1016/j.bbmt.2011.10.044.
Gonsalves WI, Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Second auto-SCT for treatment of relapsed multiple myeloma. Bone Marrow Transplant. 2013;48:568–73. https://doi.org/10.1038/bmt.2012.183.
Sellner L, Heiss C, Benner A, Raab MS, Hillengass J, Hose D, et al. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. Cancer. 2013;119:2438–46. https://doi.org/10.1002/cncr.28104.
Gimsing P, Hjertner O, Abildgaard N, Andersen NF, Dahl TG, Gregersen H, et al. Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial. Bone Marrow Transplant. 2015;50:1306–11. https://doi.org/10.1038/bmt.2015.125.
Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. 2015;21:2039–51. https://doi.org/10.1016/j.bbmt.2015.09.016.
McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279–89.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
RV: Bristol-Myers Squibb: Consultancy and Research Support; Takeda: Consultancy and Research Support; Amgen: Consultancy and Research Support; Celgene: Consultancy and Research Support; Janssen: Consultancy; Novartis: Consultancy; Jazz: Consultancy; Karyopharma: Consultancy. The remaining authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Manjappa, S., Fiala, M.A., King, J. et al. The efficacy of salvage autologous stem cell transplant among patients with multiple myeloma who received maintenance therapy post initial transplant. Bone Marrow Transplant 53, 1483–1486 (2018). https://doi.org/10.1038/s41409-018-0216-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-018-0216-3
- Springer Nature Limited
This article is cited by
-
The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
Biomarker Research (2022)
-
Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma
Bone Marrow Transplantation (2021)
-
Maintenance therapy following salvage autologous stem cell transplant in patients with multiple myeloma
Bone Marrow Transplantation (2020)